ICUD-SIU International Consultation on Bladder Cancer 2017: management of non-muscle invasive bladder cancer

Autor: Christopher B. Anderson, J. Domínguez-Escrig, Robert S. Svatek, Guilherme Godoy, Bernard H. Bochner, Trinity J. Bivalacqua, Michael A. O’Donnell, F Johannes P van Valenberg, Sam S. Chang, Antoine G. van der Heijden, Piyush K. Agarwal, Wassim Kassouf, Colin P.N. Dinney, James M. McKiernan, Jay B. Shah, Eduardo Solsona, Joost L. Boormans, Paramananthan Mariappan, J. Alfred Witjes, Girish S. Kulkarni, Cyrill A. Rentsch, Leonardo L. Monteiro
Přispěvatelé: Urology
Rok vydání: 2018
Předmět:
Male
Nephrology
medicine.medical_specialty
Urology
medicine.medical_treatment
030232 urology & nephrology
Cystectomy
Malignancy
03 medical and health sciences
0302 clinical medicine
SDG 3 - Good Health and Well-being
Adjuvants
Immunologic
Urethra
Internal medicine
Urological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15]
medicine
Humans
Neoplasm Invasiveness
Grading (tumors)
Neoplasm Staging
Urine cytology
Carcinoma
Transitional Cell
Bladder cancer
medicine.diagnostic_test
business.industry
General surgery
Carcinoma in situ
Prostate
Cystoscopy
Prognosis
medicine.disease
Administration
Intravesical
Urinary Bladder Neoplasms
030220 oncology & carcinogenesis
BCG Vaccine
Disease Progression
Neoplasm Grading
Neoplasm Recurrence
Local
Non muscle invasive
business
Carcinoma in Situ
Zdroj: World Journal of Urology, 37(1), 51-60. Springer-Verlag
World Journal of Urology, 37, 1, pp. 51-60
World Journal of Urology, 37, 51-60
ISSN: 1433-8726
0724-4983
Popis: Item does not contain fulltext PURPOSE: To provide a summary of the Third International Consultation on Bladder Cancer recommendations for the management of non-muscle invasive bladder cancer (NMIBC). METHODS: A detailed review of the literature was performed focusing on original articles for the management of NMIBC. An international committee assessed and graded the articles based on the Oxford Centre for Evidence-based Medicine system. The entire spectrum of NMIBC was covered such as prognostic factors of recurrence and progression, risk stratification, staging, management of positive urine cytology with negative white light cystoscopy, indications of bladder and prostatic urethral biopsies, management of Ta low grade (LG) and high risk tumors (Ta high grade [HG], T1, carcinoma in situ [CIS]), impact of BCG strain and host on outcomes, management of complications of intravesical therapy, role of alternative therapies, indications for early cystectomy, surveillance strategies, and new treatments. The working group provides several recommendations on the management of NMIBC. RESULTS: Recommendations were summarized with regard to staging; management of primary and recurrent LG Ta and high risk disease, positive urine cytology with negative white light cystoscopy and prostatic urethral involvement; indications for timely cystectomy; and surveillance strategies. CONCLUSION: NMIBC remains a common and challenging malignancy to manage. Accurate staging, grading, and risk stratification are critical determinants of the management and outcomes of these patients. Current tools for risk stratification are limited but informative, and should be used in clinical practice when determining diagnosis, surveillance, and treatment of NMIBC.
Databáze: OpenAIRE
Externí odkaz: